Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-016
- Development stage
- Preclinical
- Lead developer
- Sunny Pharmtech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SP-016 is a high-potency small molecule therapeutic candidate currently in the research and development (R&D) stage at Sunny Pharmtech. It is being developed for the treatment of inflammatory bowel disease (IBD) and is formulated as an oral capsule. The compound is classified under Occupational Exposure Band 4 (OEB4), which denotes a high level of pharmacological potency requiring specialized containment and handling during the manufacturing process. While the specific molecular target and mechanism of action have not been publicly disclosed, the program aligns with Sunny Pharmtech's strategic focus on developing technically challenging, high-potency pharmaceutical products and complex specialty formulations.
Beyond the preview
Go deeper on SP-016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-016.